Abstract

BackgroundmiRNA-105 has been reported in a vast number of malignancies, including hepatocellular carcinoma and colorectal, esophageal, breast and non-small lung cancers. Still, the biological role of miR-105 remains mostly uncovered in oral squamous cell carcinoma (OSCC).MethodsmiR-105 expression in OSCC tissues and cell lines was detected by qRT-PCR. Survival analysis was performed using the Kaplan–Meier method, while the prognostic significance of miR-105 was evaluated by Cox regression analysis with a cohort of 90 OSCC patients. The effects of miR-105 on the proliferation of tumor cells were analyzed by CCK-8 assay and crystal violet staining, while cell invasion was assessed by transwell assays.ResultsOur current work indicates that miR-105 was upregulated in human OSCC tissues and cell lines. Moreover, miR-105 expression was closely associated with tumor size as well as clinical and differentiation stages. Notably, an elevated expression of miR-105 may predict some poor clinical prognosis in OSCC patients. Furthermore, miR-105 overexpression can significantly promote the proliferation and invasion of OSCC cells, whereas downregulation of miR-105 inhibits these cellular events.ConclusionThis study demonstrates that miR-105 can promote the proliferation and invasion of OSCC cells. High expression of miR-105 predicts poor prognosis for OSCC and, therefore, it may represent a prognostic biomarker and putative therapeutic target for patients affected by OSCC.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.